Establishment Labs: Procedure Economics Strengthens The Bull Case

Establishment Labs is leveraging FDA approval and U.S. market entry to drive higher-margin growth through procedure-based offerings like Preservé. Q2 2026 results showed 31.7% revenue growth, gross margin expansion to 70.6%, and U.S. sales accounting for 89% of total growth. Preservé delivers over 2x revenue per procedure versus traditional augmentation, but long-term success hinges on repeat utilization and durable economics. Valuation is demanding at 8.91x forward EV/sales; execution risks around Preservé adoption, safety outcomes, and cash flow conversion require close monitoring. Morsa Images/DigitalVision via Getty Images Beyond Implant Volume Establishment Labs ( ESTA ) could increase its revenue per breast augmentation procedure by offering patients and surgeons more than an implant alone. The distinction between growing its product volume and increasing revenue